cigna glp-1 Cigna's Evernorth launches Wegovy, Zepbound copayment cap Cigna will stop covering GLP-1

Description

While studies sponsored by leading pharmaceutical companies suggest a much higher likelihood of weight regain, those studies are not reflective of the average person with obesity

Each positive trial result moves the molecule closer to NDA submission

And, while there is no consensus on the cause of this growing obesity rate reduction in physical activity, increase in dietary fat, increase in sugar and sugary beverages, increase in ultra-processed foods, higher cost of healthier diets theres no denying that Americans need solutions

In addition, tirzepatide, even at the lowest maintenance dose of 5 mg, can reduce body weight to a greater extent compared with GLP-1 RAs including subcutaneous semaglutide which, in turn, has been shown to be superior to other glucose-lowering agents [28]

Read the full article here: #Type1Diabetes #SmartMDI #GlycemicControl #Endocrinology #RealWorldEvidence #DiabetesCare To view or add a comment, sign in One Medicine